Please assess the completion status of the following clinical trial:

Trial Title: Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Size of the defect on the femoral cartilage:one or two symptomatic lesion(s) grade III-IV from 2 cm2 to 8 cm2 at the femoral condyle and/or trochlea~* Other:~* Age: 18-55 years~* Written informed consent by the patient~Exclusion Criteria:~* Defect:~  * Lesions smaller than 2cm2 or greater than 8cm2~ * Total area of all lesions bigger than 8cm2~ * Lesions other than on the femoral condyle and/or trochlea~ * Any evidence of the following diseases in the target joint: septic arthritis; inflammatory joint disease; gout; recurrent episodes of pseudogout; Paget disease of bone; ochronosis; acromegaly; hemochromatosis;Wilson disease; primary osteochondromatosis; heritable disorders; collagen gene mutations~ * Presence of a clinically relevant cartilage lesion on the patella (second lesion)~ * Patellofemoral cartilage lesion~ * Presence of relevant complex knee injuries affecting bone and/or ligaments~ * Osteochondritis dissecans: recent (within 1 year before baseline); depth of lesion \>0.5 cm; subchondral sclerosis~ * Advanced osteoarthritis (as defined by Radiographic Atlas of Osteoarthritis, grade 2-3)~ * Varus or valgus malalignment exceeding 5° (kissing lesions out)~* Medical history:~  * gravidity (Pregnancy)~ * breast feeding~ * presence of multiple severe allergies (including porcine collagen, streptomycin and penicillin)~ * Osteoarthritis~ * Current diagnosis of osteomyelitis~ * Any clinically significant or symptomatic vascular or neurologic disorder of the lower extremities~ * A blood result showing liver enzymes (serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase) of more than 2 times the upper limit of normal or any other result that in the clinical investigator's mind is clinically important~ * C-reactive protein level greater than 10 mg/L~ * Uncontrolled diabetes~ * Renal insufficiency~ * Previous pacemaker implantation~ * Any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee~ * Mosaicplasty (osteochondral autograft transfer system)~ * Microfracture performed less than 1 year before baseline~ * Received hyaluronic acid intra-articular injections into the afflicted knee within the last 6 months of baseline Meniscal transplant (previous/present)~ * Meniscal suture with meniscal arrows ipsilaterally (present or previous if not resorbed)~ * Taking specific osteoarthritis drugs, such as chondroitin sulfate, diacerein, n-glucosamine, piascledine, and capsaicin, within 2 weeks of the baseline visit~ * Corticosteroid therapy by systemic or intra-articular route within the last month of baseline or intramuscular or oral corticosteroids within the last 2 weeks of baseline~ * Chronic use of anticoagulants~ * Patients with human immunodeficiency virus, hepatitis, or syphilis~ * Malignancy~ * Alcohol and drug (medication) abuse~ * Poor general health condition as judged by investigator~ * Body mass index \>35 kg/m2~ * Medication:chronic treatment with steroids or growth factors (immunomodulatory drugs)~* Other:~  * Participation in concurrent clinical trials~ * Participation in a previous clinical trial within 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Implantation of cartilage graft (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).